Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Cash from Investing Activities (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Cash from Investing Activities data on record, last reported at $5.7 million in Q2 2025.

  • For Q2 2025, Cash from Investing Activities fell 12.44% year-over-year to $5.7 million; the TTM value through Sep 2025 reached $26.5 million, down 13.41%, while the annual FY2024 figure was $19.8 million, 33.66% down from the prior year.
  • Cash from Investing Activities reached $5.7 million in Q2 2025 per RANI's latest filing, down from $18.2 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $18.2 million in Q1 2025 and bottomed at -$71.3 million in Q3 2022.
  • Average Cash from Investing Activities over 5 years is $39352.9, with a median of $789000.0 recorded in 2023.
  • Peak YoY movement for Cash from Investing Activities: tumbled 178.68% in 2022, then skyrocketed 3004.6% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$271000.0 in 2021, then plummeted by 68.63% to -$457000.0 in 2022, then surged by 3004.6% to $13.3 million in 2023, then crashed by 81.01% to $2.5 million in 2024, then soared by 126.62% to $5.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $5.7 million in Q2 2025, $18.2 million in Q1 2025, and $2.5 million in Q4 2024.